Wellington owns less than 5% of Genmab shares

In early July, the investment firm increased its stake in the Danish biotech firm to more than 5%, but Genmab now reports that this is no longer the case.

Photo: Joost Melis / Genmab / PR

US-based private investment firm Wellington Management Group LLP has decreased its share holding in Genmab to 4.9%, the Danish biotech firm reports in a Wednesday press release.

Earlier in July, the investment firm had actually increased its ownership share beyond 5% to a total of 5.02%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs